Introduction

Schizophrenia is a severe and persistent mental health disorder that affects more than 23 million people worldwide (WHO, 2018) and is associated with cognitive dysfunction and poor functional capacity in nearly all domains (Harvey & Strassing, 2012). People with schizophrenia also have a 20% shorter life span than people in the general population (Newman & Bland, 1991), and the mortality gap between people with schizophrenia and the general population is increasing (Saha et al., 2007). Although rates of completed suicide are higher in people with schizophrenia than in the general population (Baxter & Appleby, 1999), the greatest contributor to the heightened risk of premature death in people with schizophrenia is early mortality due to chronic diseases (Ösby et al., 2000).

The largest contributors to chronic disease-related deaths in people with schizophrenia are cardiovascular diseases and cancer (Crump et al., 2013; Polednak, 2014; Westman et al., 2018). Observational research conducted over the past three decades has consistently linked schizophrenia with an increased risk of cancer mortality (Zhuo et al., 2017; Tanskanen et al., 2018). Studies have shown that the occurrence of risk factors for cancer, such as heavy smoking, drug and alcohol abuse, poor diet and lack of exercise, in people with schizophrenia is higher than in the general population (Brown et al., 1999; Hartz et al., 2014; Hunt et al., 2018; Jakobsen et al., 2018). People with schizophrenia may also have compromised access to general health care resources (Brown et al., 1999; Mitchell et al., 2012).

However, research results on the relationship between schizophrenia and cancer incidence have been less consistent than results on the relationship between schizophrenia and cancer mortality (Hodgson et al., 2010). A number of early studies reported unexpectedly low rates of cancer in people with schizophrenia despite an over-representation of cancer risk factors...
We conducted a population-based study of the incidence of seven common types of cancer in 111,306 people with a hospital diagnosis of schizophrenia, using three comprehensive registries in Sweden and accounting for the effects of age, sex and calendar time. We chose to study a number of specific cancer sites either characterised by high mortality in the Swedish population or an association with adverse lifestyle factors that are also over-expressed in people with schizophrenia (e.g. smoking, alcohol consumption, physical inactivity and poor diet), or both (Regier et al., 1990; Hung et al., 2014; Marenmanni et al., 2017; Vancamfort et al., 2017; Firth et al., 2018; Jakobsen et al., 2018). We hypothesised that cancers associated with these specific lifestyle factors are more common in people with schizophrenia than in the general population.

Methods

Study population and data sources

This study compared the incidence of cancer in people in Sweden diagnosed with schizophrenia with the incidence of cancer in the total population of Sweden between 1990 and 2013. Schizophrenia diagnoses were obtained from the National Patient Register and incident cancer diagnoses from three nationwide registers: the Cancer Register, the National Patient Register and the Cause of Death Register.

Identification of patients with schizophrenia

The National Patient Register, which contains comprehensive information on psychiatric inpatient care nationwide from 1973 onward, was used to identify all people 15 years or older who were admitted to the hospital and received a main diagnosis of schizophrenia between 1 January 1973 and 31 December 2013 (n = 137,535). Diagnoses of schizophrenia were identified using WHO’s International Statistical Classification of Diseases (ICD-8 and ICD-9 diagnosis codes 295, 297 and 298 (1973–1996) and ICD-10 diagnosis codes F20 to F29 (1997–2013). When measured as the proportion of true cases, using chart review as the gold standard, coverage of schizophrenia diagnoses in the National Patient Register is 84% (Dalman et al., 2002; Nesvåg et al., 2017).

Identification of incident cancer cases

Information on cancer diagnoses from 1 January 1973 through 31 December 2013 was obtained from the Swedish Cancer Register, National Patient Register and Cause of Death Register (Ludvigsson et al., 2016). Individual-level data from these sources were linked via a pseudonymised version of the personal identification number, assigned to all Swedish citizens and permanent residents. When an individual had a diagnosis of the same cancer in more than one register, the earliest diagnosis was used. We used 1 January 1973 to 31 December 1989 as a wash-out period to eliminate people diagnosed with cancer prior to the start of the study.

The Swedish Cancer Register gathers comprehensive data on diagnoses of cancer in the whole population of Sweden (Barlow et al., 2009). The National Patient Register includes nationwide coverage of inpatient diagnoses of somatic diseases from 1987. The Cause of Death Register, established in 1961, includes data on cause(s) of death for all people registered in Sweden, including information from death certificates about date of death and main (underlying) and additional causes of death. The ICD-7 (Cancer Register) and ICD-9 and ICD-10 codes (National Patient Register and Cause of Death Register) are given in Table 2.

Study population and follow-up

People with diagnosed schizophrenia were followed up starting on the date of their first hospital admission for schizophrenia or 1 January 1990, whichever came last. Follow-up ended on the earliest of the following four dates: date of cancer diagnosis, date of death, date of emigration or 31 December 2013. Of the 137,535 people diagnosed with schizophrenia between 1973 and 2013, a total of 20,979 died and 5,250 were diagnosed with cancer before the start of the study period in 1990, leaving 111,306 people in the schizophrenia cohort.

For the total population of Sweden (the comparison group), we obtained the number of people for each year in the study period, stratified by sex and age group, from Statistics Sweden, the Swedish national statistical agency.

Statistical analysis

The overall and site-specific cancer incidence rates in people with schizophrenia were compared with incidence rates in the general population.
population, each calculated as the ratio of the number of incident cases to the number of person-years of follow-up. Poisson regression models were used to compare overall and site-specific cancer incidence rates in people with schizophrenia to those of the general population by estimating incidence rate ratios (IRRs) with 95% confidence intervals (CIs). The logarithm of the person-years of follow-up was used as the offset parameter. All models were adjusted for sex, calendar year and age at the time of follow-up. Models were also estimated separately for men and women, by study period (1990–1996, 1997–2004 and 2005–2013) and by age group (15–39, 40–65 and 65 and older).

## Results

The 111 306 people with schizophrenia contributed a total of 1 424 829 person-years of follow-up (Table 1). They were predominantly middle-aged (mean [s.d.] age, 49 ± 20 years) and female (53%).

### Overall incidence of cancer

Among those with diagnosed schizophrenia, a total of 11 670 cases of cancer were identified (Table 2). There was no significant difference in the overall incidence of cancer compared to the general population (IRR 1.02, 95% CI 0.91–1.13). No significant differences in IRRs of overall cancer were found by age group or period (data not shown).

Sex-stratified analyses showed a slightly decreased incidence in men with schizophrenia (IRR 0.93, 95% CI 0.89–0.98) and a slightly increased incidence in women with schizophrenia (IRR 1.11, 95% CI 1.08–1.15). The incidence of cancer was lower in men with schizophrenia than in men in the general population during the third period (2005–2013, IRR 0.89, 95% CI 0.81–0.96) but not the first two (1990–1996 and 1997–2004). The incidence of cancer remained higher in women with schizophrenia than in women in the general population during all three periods (data not shown).

The overall incidence of cancer in the age group 75 years and older was lower in people with schizophrenia (IRR 0.90, 95% CI 0.86–0.94). This pattern can also be seen in Fig. 1a. When stratified by sex, the overall incidence of cancer was lower in men with schizophrenia in the age group 65 years and older (IRR 0.86, 95% CI 0.80–0.92) (Fig. 1b). However, after an additional analysis that excluded prostate cancer, the lower incidence in this age group disappeared (IRR 0.96, 95% CI 0.92–1.02), and in the 40–64 years age group, a higher cancer incidence was observed among men with schizophrenia (IRR 1.26, 95% CI 1.19–1.33). The overall incidence of cancer was significantly higher in women with schizophrenia who were 40–64 years (IRR 1.22, 95% CI 1.16–1.28) and 65 years and older (IRR 1.05, 95% CI 1.02–1.09), than in the general population (Fig. 1c).

### Site-specific incidence of cancer

People with schizophrenia had a significantly higher incidence of cancers of the lung, oesophagus, pancreas and breast than people in the general population (Table 2). On the other hand, men with schizophrenia had a lower incidence of prostate cancer (IRR 0.66, 95% CI 0.55–0.79). There was no significant association between schizophrenia and incidence of cancer of the stomach or colon. Significantly higher incidence of oesophageal cancer and of pancreatic cancer was observed in men only.

After stratifying for time period (Table 3), we found that women with schizophrenia had an excess risk of breast cancer in all three periods (1990–1996, IRR 1.22, 95% CI 1.09–1.37; 1997–2004, IRR 1.17, 95% CI 1.06–1.30; and 2005–2013, IRR 1.18, 95% CI 1.08–1.30). The incidence of lung cancer was elevated in people with schizophrenia during the second (IRR 1.37, 95% CI 1.14–1.65) and third (IRR 1.64, 95% CI 1.41–1.89) periods of the study. Similarly, the incidence of oesophageal cancer was significantly higher in people with schizophrenia during the second (IRR 1.39, 95% CI 1.08–1.79) and third (IRR 1.29, 95% CI 1.01–1.63) study periods. The incidence of prostate cancer was decreased in men with schizophrenia during the second (IRR 0.67, 95% CI 0.48–0.93) and third (IRR 0.60, 95% CI 0.45–0.80) study periods.

In analyses that were stratified by age group, the incidence of lung cancer was elevated in people with schizophrenia across all groups, but the incidence estimates decreased with increasing age strata (15–39 years, IRR 2.49, 95% CI 1.50–4.11; 40–64 years, IRR 1.90, 95% CI 1.67–2.15; and 65 years or older, IRR 1.21, 95% CI 1.05–1.39). There was an excess incidence of breast cancer in women with schizophrenia aged 40–64 years (IRR 1.19, 95% CI 1.09–1.29) and 65 years and older (IRR 1.21, 95% CI 1.10–1.32). The incidence of pancreatic cancer was significantly increased in people with schizophrenia between the ages of 15 and 39 years (IRR 2.93, 95% CI 1.16–2.31) and 40–64 years (IRR 1.31, 95% CI 1.10–1.56). The incidences of oesophageal (IRR 1.53, 95% CI 1.21–1.93) and stomach cancer (IRR 1.43, 95% CI 1.17–1.74) were significantly higher in people with schizophrenia.

### Table 1. Demographic and follow-up characteristics of people with schizophrenia in Sweden, in total and by sex, from 1990 through 2013

| Characteristic         | Total     | Men        | Women       |
|------------------------|-----------|------------|-------------|
| N, total               | 111 306   | 52 044     | 59 262      |
| Age, years             |           |            |             |
| Mean (s.d.)            | 49.9 (19.8)| 44.6 (18.3)| 53.0 (20.3) |
| Median                 | 45.0      | 41.0       | 51.0        |
| Follow-up, years       |           |            |             |
| Mean (s.d.)            | 12.8 (8.5)| 13.0 (8.5) | 12.6 (8.4)  |
| Median                 | 12.3      | 12.8       | 11.9        |
| Follow-up, total person-years | 1 424 829 | 678 656    | 746 829     |

s.d., standard deviation.
schizophrenia only in the 40–64 years age group. The incidence of prostate cancer was significantly lower in men with schizophrenia who were 40–64 (IRR 0.54, 95% CI 0.44–0.66) and 65 or older (IRR 0.70, 95% CI 0.56–0.88), whereas the incidence of colon cancer was significantly lower in people with schizophrenia only in those 65 years or older (IRR 0.90, 95% CI 0.83–0.97).

Discussion

Main findings

In this population-based study, we found the same overall risk of cancer in people with schizophrenia as in the general population. However, we found a higher overall cancer risk among women with schizophrenia. The overall cancer risk for men was reduced among men with schizophrenia but the reduced risk disappeared when excluding prostate cancer from the analysis. We found a pattern of relative incidence rates among schizophrenia patients being higher in lower age groups when stratifying the analyses for age. A notable exception was observed for prostate cancer, where relative incidence rates were lower among younger men with schizophrenia. People with schizophrenia had a higher risk of lung, oesophageal and pancreatic cancer, women with schizophrenia had a higher risk of breast cancer, and men with schizophrenia had a lower risk of prostate cancer than the general population. Also some noteworthy differences in the overall and site-specific incidences of cancer by age category and by sex were observed.

The increased relative incidences in the schizophrenic population observed for lung, oesophageal, pancreatic and breast cancer were expected due to the higher prevalence of heavy smoking, alcohol use, obesity and lack of exercise in this population (Brown et al., 1999; von Hausswollf-Juhlin et al., 2009; Hartz et al., 2014; Hunt et al., 2018; Jakobsen et al., 2018). The decreased incidence of prostate cancer compared to the general population can probably be explained by lower rates of detection by opportunistic prostate cancer screening. Prostate cancer screening is not part of the national screening programme in Sweden but testing is available at low cost within the Swedish health care system at patient’s request.

Comparison with previous studies

Our finding of no excess overall risk of cancer associated with schizophrenia is broadly consistent with the findings of a meta-analysis of six studies that was published in 2008 (Catts et al., 2008) but contrasts with the results of a more recent and larger meta-analysis of 16 cohort studies that found a small but statistically significant decreased risk of cancer in people with schizophrenia (Li et al., 2018). The inconsistencies in the conclusions of these two meta-analyses reflect the inconsistencies in the results of the individual studies. Indeed, in the meta-analysis by Li et al. (2018), the percentage of total variation across studies was more than 90%, which indicates a high degree of inconsistency in the results of the individual studies (Higgins et al., 2003). Li et al. (2018) advised that incidence risk ratios should be calculated for individual cancer types and separately for men and women.

Similar to the pooled analyses (Li et al., 2018) and an Israeli study (Agay et al., 2017), we found a significantly lower risk of prostate cancer in men and a significantly higher risk of lung cancer in women with schizophrenia. In line with the findings from two meta-analyses of observational studies that focused on the association between schizophrenia and female breast cancer (Xiping et al., 2018; Zhuo and Triplett, 2018), we found a higher incidence of breast cancer in women with schizophrenia. Our findings are also consistent with two more recently-published population-based cohort studies that documented significantly higher risk of newly-diagnosed breast cancer in women with schizophrenia (Wu et al., 2017; Chen et al., 2018). Few additional noteworthy sex differences in the risk of specific cancers in people with schizophrenia were observed in our study. In summary, the observations in our study are broadly consistent with recently-published pooled analyses of data from cohort studies investigating the sex-specific risks of individual cancer subtypes in people with schizophrenia.

---

Table 2. Incidence rate ratios (IRRs) of cancer in people with schizophrenia in Sweden from 1990 through 2013*

| Cancer site | Cancer cases (n) | IRR (95% CI) |
|-------------|------------------|--------------|
| Any site    |                  |              |
| Men         | 4573             | 0.93 (0.89–0.98) |
| Women       | 7097             | 1.11 (1.08–1.15) |
| Total       | 11 670           | 1.02 (0.91–1.13) |
| Lung        |                  |              |
| Men         | 722              | 1.49 (1.35–1.63) |
| Women       | 769              | 1.40 (1.27–1.55) |
| Total       | 1491             | 1.42 (1.28–1.58) |
| Oesophagus  |                  |              |
| Men         | 106              | 1.29 (1.05–1.58) |
| Women       | 54               | 1.16 (0.91–1.47) |
| Total       | 160              | 1.25 (1.07–1.46) |
| Pancreas    |                  |              |
| Men         | 207              | 1.22 (1.07–1.39) |
| Women       | 285              | 1.03 (0.92–1.16) |
| Total       | 492              | 1.10 (1.01–1.21) |
| Stomach     |                  |              |
| Men         | 178              | 1.13 (0.97–1.31) |
| Women       | 146              | 0.95 (0.80–1.12) |
| Total       | 324              | 1.03 (0.92–1.17) |
| Colon       |                  |              |
| Men         | 366              | 0.91 (0.81–1.01) |
| Women       | 610              | 0.97 (0.89–1.05) |
| Total       | 976              | 0.94 (0.87–1.01) |
| Prostate    |                  |              |
| Men         | 1111             | 0.66 (0.55–0.79) |
| Breast      |                  |              |
| Women       | 2189             | 1.19 (1.12–1.26) |

*IRRs were estimated by using Poisson regression models comparing overall and site-specific cancer incidence rates in people with schizophrenia to those of the general population. The reference group was the general population of Sweden. Lung: ICD-7: 162, ICD-9: 162C-162D, 162W, ICD-10: C34; Oesophagus: ICD-7: 150, ICD-9: 150, ICD-10: C15; Pancreas: ICD-7: 157, ICD-9: 157, ICD-10: C25; Stomach: ICD-7: 151, ICD-9: 151, ICD-10: C16; Colon: ICD-7: 153, ICD-9: 153, ICD-10: C18; Prostate: ICD-7: 187, ICD-9: 185, ICD-10: C61; Breast: ICD-7: 170, ICD-9: 174, ICD-10: C50.
Fig. 1. Incidence rate ratios (IRRs) of any cancer in people with schizophrenia and in the general population by age and sex, 1990 through 2013.
Some of the cancer types that were the focus of this study were chosen based primarily on their association with adverse lifestyle factors that are also highly-prevalent in people with schizophrenia. For instance, a population-based retrospective cohort study of people with diagnosed mental health disorders found significant associations between female breast cancer and alcohol use and the presence of metabolic syndrome; between lung cancer and tobacco use; between oesophageal cancer and tobacco and alcohol use; and between pancreatic cancer and the use of tobacco (Hung et al., 2014). These results are consistent with the extensive literature that identifies lifestyle factors such as unhealthy diet, excessive body weight, physical inactivity, excessive alcohol consumption and smoking behaviours as modifiable risk factors for developing breast, prostate, lung and colon cancers in the broader population (Khan et al., 2010; Weiderpass, 2010) and for reducing cancer-related deaths (Islami et al., 2018). We lacked specific information on the prevalence of unhealthy lifestyle-related risk factors among people with schizophrenia residing in Sweden. A national register study that used 1987–2010 data from the entire Swedish population aged 15 years or older showed that people with diagnosed schizophrenia had a threefold higher mortality from cardiovascular diseases than people in the general population (Westman et al., 2018). Inasmuch as smoking, alcohol consumption, poor diet and sedentary lifestyle are risk factors common to both cardiovascular diseases and lifestyle-related cancers, the high prevalence of these risk factors in people with schizophrenia in other parts of the world highlights the considerable potential for reducing the risk of lifestyle-related cancers as well as premature death from cardiovascular causes worldwide (Regier et al., 1990; Hung et al., 2014; Maremmanni et al., 2017; Vancamfort et al., 2017; Firth et al., 2018; Jakobsen et al., 2018).

Our study found that people with schizophrenia had a significantly higher incidence of oesophageal cancer. The risk was significantly increased for men but not women. In a nested case–control study that included 40,441 incident cases of six different types of cancer, researchers found no higher risk of gastrointestinal cancer in people with schizophrenia (Hippisley-Cox et al., 2007). In that study, gastric and oesophageal cancers were combined, whereas in our study, they were analysed separately. No other population-based studies have reported the comparative risks of oesophageal cancer, discretely, in people with schizophrenia.

Our study also provides new information about schizophrenia and the risk of pancreatic cancer. We observed an increased risk of pancreatic cancer in people with schizophrenia. Stratification by sex showed an increased risk in men but not in women. We are aware of only one nationwide, population-based cohort study of the risk of pancreatic cancer in people with schizophrenia (Lin et al., 2013a). That study showed a lower risk of pancreatic cancer in patients with schizophrenia than in the general population of Taiwan. They excluded metastatic malignancies from their analyses to reduce misclassification of the primary tumour site. However, because people with schizophrenia are typically diagnosed at a later stage of cancer (Kisely et al., 2008), excluding metastatic malignancies may have led to an underestimation of cancer diagnoses in people with schizophrenia.

In our study, we observed a decreased overall cancer risk in people with schizophrenia 75 years and older. This observation is in line with findings from prior research showing that the incidence rates of cancer in people with schizophrenia may decline with increasing age (Dalton et al., 2004; Lin et al., 2013a, 2013b). The underlying causes of this age-related trend are unknown, but may be caused by selection where the small fraction of the schizophrenia population that reaches high age are physiologically healthier or have less risk factors than the general population of the same age. Cancer and cardiovascular disease, the other leading cause of death in Sweden, share several risk factors, such as smoking, alcohol use, obesity and physical inactivity. If schizophrenia modifies the effect of risk factors common between cancer and cardiovascular disease such that the effect on the risk of death is larger in people with schizophrenia, the prevalence of risk factors will decrease faster among people with schizophrenia as the populations age. We suggest two possible mechanisms through which schizophrenia could modify the effect of risk factors: (1) by increasing the probability of a dichotomous distribution of the risk factor, for example, smokers tending to be heavy smokers and obese people tending to be severely obese; and (2) increasing the probability of having a combination of risk factors. However, the Swedish national health register data do not include information on exposure to such lifestyle factors and we did not address

### Table 3. Incidence rate ratios (IRRs) of cancer in people with schizophrenia in Sweden from 1990 through 2013 by period

| Cancer          | 1990–1996 | 1997–2004 | 2005–2013 |
|-----------------|-----------|-----------|-----------|
| Any site        | 3202      | 3752      | 4716      |
| Lung            | 298       | 458       | 735       |
| Oesophagus      | 33        | 59        | 68        |
| Pancreas        | 133       | 158       | 201       |
| Stomach         | 108       | 101       | 115       |
| Colon (men)     | 263       | 292       | 421       |
| Prostate (men)  | 262       | 366       | 483       |
| Breast (women)  | 573       | 728       | 888       |

*IRRs were estimated by using Poisson regression models comparing overall and site-specific cancer incidence rates in people with schizophrenia to those of the general population. The reference group was the general population of Sweden.
the relative impact of early mortality from non-cancer-related causes on the incidence of new cancer diagnoses in this work.

Several lines of evidence suggest that people with schizophrenia may experience accelerated ageing (Kirkpatrick et al., 2008; Kirkpatrick and Kennedy, 2018). These include earlier manifestations of cognitive decline, diabetes and other age-associated chronic diseases (Kirkpatrick et al., 2008), as well as the early expression of a wide variety of biomarkers related to the ageing process (Kirkpatrick and Kennedy, 2018). It is not clear whether a potentially heightened risk of some types of cancers in younger and middle-aged people with schizophrenia can be attributed to accelerated ageing.

**Strengths and limitations**

The Swedish Cancer Register has nationwide coverage (Barlow et al., 2009) and is well-suited for measuring cancer incidence in the general population. However, the register’s completeness of incidence in people with schizophrenia may be limited. Underreporting is more likely for those whose histology or cytology verification is missing, which most commonly occurs when cancer is diagnosed at an advanced stage and the patient receives only palliative care (Barlow et al., 2009). People with schizophrenia have low rates of participation in general health and cancer screening programmes (Fujiwara et al., 2017; Hwong et al., 2020; Solmi et al., 2020), and delayed and late-stage cancer diagnoses are common in this patient population (Farasatpour et al., 2013). To compensate the underreporting in the Swedish Cancer Register and minimise possible differential completeness in reporting, we used additional data on incident cancers from other nationwide registers, including the National Patient Register or the Swedish Cause of Death Register.

To the best of our knowledge, the current study is the largest to date with respect to the number of individuals with diagnosed schizophrenia. An additional strength of the study was the analysis by calendar period of follow-up. The mean (49 years) and median (45 years) age and age span (up to more than 80 years) of the schizophrenia cohort in the study were also advantageous, as they allowed us to compare incidence in age groups for which the risk of incident cancer is most relevant, including advanced age.

There are also limitations to consider. This study used data from computerised, linked registers. These data were collected for purposes other than for research, and may be subject to misclassification. Additionally, given that this was a register-based study, our findings are restricted to the incidence of diagnosed cancer. Even though the underlying population in this study had universal health coverage, the true incidence of cancer is likely obscured by low participation in general preventive health services and cancer screening programmes that is frequently observed in people with schizophrenia (Mitchell et al., 2012; Liu et al., 2017; Irwin et al., 2019). This bias would be especially problematic when studying cancers with less acute courses (e.g. prostate, skin or thyroid cancer), while this bias would be less of a concern when studying cancers that are often detected when acute symptoms are already present (e.g. lung, oesophageal and stomach cancers). Although the schizophrenia cohort in this study was large, because of sample size limitations, we were not able to study the comparative risks of all cancer types, including important but rarer malignancies. Some of the statistically significant associations between schizophrenia and some site-specific cancers, such as the results on oesophageal and pancreatic cancer, must be interpreted with caution given small effects (IRR near 1) and evidence of low precision (wide 95% CIs). We were unable to examine the impacts of a variety of susceptibility factors on cancer incidence in this study, including family history, genetic characteristics, use of antipsychotic drugs and other medications, reproductive history and lifestyle factors. We suggest national health information systems should include comprehensive registration on primary health care visits, and collection of these data should include also information on BMI, smoking and alcohol consumption. Further, our data lacked information on the stage of cancer. This is an important consideration given the likelihood that people with schizophrenia present with a more advanced stage of cancer at the time of diagnosis (Toender et al., 2018) – a factor that has been associated with worse cancer survival in people with pre-existing mental disorders (Davis et al., 2020). Others have documented a significantly higher proportion of individuals with evidence of metastatic disease at presentation in people with psychiatric illness (Kisely et al., 2013). The availability of information on cancer stage at diagnosis will be an important consideration for future population-based studies of cancer incidence and survival in people with severe mental illnesses as it could add information about the mechanisms behind the high cancer mortality among schizophrenia patients. In our study, follow-up was available until 2013, and we did not have complete data for the analysis of cancer risk beyond that time. Finally, all study data came from the population of Sweden, so the risk estimates may not generalise to people living in other parts of the world.

**Conclusions**

There was no overall higher risk of cancer in people with schizophrenia than in the general population in this population-based study. However, people with schizophrenia had a higher risk of lung, oesophageal and pancreatic cancer; women with schizophrenia had a higher risk of breast cancer; and men with schizophrenia had a lower risk of prostate cancer than the equivalent groups of people in the general population. The observed differences in incidence between schizophrenia patients and the general population correspond to known differences in lifestyle factors or, for prostate cancer, expected differences in tumour detection through differential participation in opportunistic screening outside of the national screening programmes. Some noteworthy sex-specific differences in cancer risk were observed. A lower overall risk of cancer was observed in people with schizophrenia aged 75 years or more than in the same age group in the general population.

**Data**

The Swedish register data have been given for this specific study, and the data cannot be shared without authorisation from the register keepers.

**Financial support.** The study has been funded by NIMH, AHRQ and the Mayo Foundation for Medical Education and Research in the USA.

**Conflict of interest.** The authors report no conflict of interest.

**References**

Agay N, Flaks-Manov N, NItzan U, Hoshen MB, Levkovitz Y and Munitz H (2017) Cancer prevalence in Israeli men and women with schizophrenia. *Psychiatry Research* **258**, 262–267.
Ananth J and Burnstein M (1977) Cancer: less common in psychiatric patients? Psychosomatics 18, 44–46.

Barak Y, Achiron A, Mandel M, Mirecki I and Aizenberg D (2005) Reduced cancer incidence among patients with schizophrenia. Cancer 104, 2817–2821.

Barlow L, Westergren K, Holmberg L and Talbark M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncologica 48, 27–33.

Baxter D and Appleby L (1999) Case register study of suicide risk in mental disorders. British Journal of Psychiatry 175, 322–326.

Brink M, Green A, Bojesen AB, Lamberti JS, Conwell Y and Andersen K (2017) Excess medical comorbidity and mortality across the lifespan in schizophrenia: a nationwide Danish register study. Schizophrenia Research 206, 347–354.

Brown S, Birtwistle J, Roe I and Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29, 697–701.

Busche CJ and Hodgson R (2010) Schizophrenia and cancer: in 2010 do we understand the connection? Canadian Journal of Psychiatry 55, 761–767.

Catala-Lopez F, Suarez-Pinilla M, Suarez-Pinilla P, Valderas JM, Catts VS, Catts SV, O(2013) Crump C, Winkleby MA, Sundquist K and Sundquist J (2019) Excess medical comorbidity and mortality across the lifespan in schizophrenia: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychological Medicine 39, 133–141.

Catts VS, Catts SV, O’Toole BI and Frost AD (2008) Cancer incidence in patients with schizophrenia and their first-degree relatives – a meta-analysis. Acta Psychiatrica Scandinavica 117, 322–336.

Chen LY, Hung YN, Chen YY, Yang SY, Pan CH, Chen CC and Kuo CJ (2018) Cancer incidence in young and middle-aged people with schizophrenia: nationwide cohort study in Taiwan, 2000–2010. Epidemiology and Psychiatric Sciences 27, 146–156.

Chou FH, Tsai KY, Su CY and Lee CC (2011) The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophrenia Research 129, 97–103.

Chou FH, Tsai KY, Wu HC and Shen SP (2016) Cancer in patients with schizophrenia: what is the next step? Psychiatry and Clinical Neurosciences 70, 473–488.

Cohen M, Dembling B and Schorling J (2002) The association between schizophrenia and cancer: a population-based mortality study. Schizophrenia Research 57, 139–146.

Crump C, Winkleby MA, Sundquist K and Sundquist J (2013) Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. American Journal of Psychiatry 170, 324–323.

Dalman C, Broma J, Cullberg J and Albeck P (2002) Young cases of schizophrenia identified in a national inpatient register – are the diagnoses valid? Social Psychiatry and Psychiatric Epidemiology 37, 527–531.

Dalton SO, Laursen TM, Melhemkjaer L, Johansen C and Mortensen PB (2004) Risk for cancer in parents of patients with schizophrenia. American Journal of Psychiatry 161, 903–908.

Dalton SO, Melhemkjaer L, Thomassen L, Mortensen PB and Johansen C (2005) Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969–1993. Schizophrenia Research 75, 315–324.

Davis LE, Bogner D, Coburn NG, Hanna TP, Kurdyak P, Groome PA and Mahar LA (2020) Stage at diagnosis and survival in patients with cancer and a pre-existing mental illness: a meta-analysis. Journal of Epidemiology and Community Health 74, 84–94.

Farasatpour M, Janardhan R, Williams CD, Margenthaler JA, Virgo KS and Johnson FE (2013) Breast cancer in patients with schizophrenia. American Journal of Surgery 206, 798–804.

Firth J, Stubbs B, Teasdale SB, Ward PB, Veronese N, Shivappa N, Hebert JR, Berk M, Yung AR and Sarris J (2018) Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry 17, 365.

Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D and Capdevielle D (2012) Antipsychotic drugs: pro-cancer or anti-cancer? A systematic review. Medical Hypotheses 79, 38–42.

Fujiwara M, Inagaki M, Nakaya N, Fujimori M, Higuchi Y, Hayashibara C, So R, Kakuda K, Kodama M, Uchitomi Y and Yamada N (2017) Cancer screening participation in schizophrenic outpatient and the influence of their functional disability on the screening rate: a cross-sectional study in Japan. Psychiatry and Clinical Neurosciences 71, 813–825.

Goldacre MJ, Kurina LM, Wotton CJ, Yeates D and Seagroatt V (2005) Schizophrenia and cancer: an epidemiological study. British Journal of Psychiatry 187, 334–338.

Grinshpoon A, Barchana M, Ponizovsky A, Lipshitz I, Nahon D, Tal O, Weizman A and Levav I (2005) Cancer in schizophrenia: is the risk higher or lower? Schizophrenia Research 73, 333–341.

Gulbinat W, Dupont A, Jablensky A, Jensen OM, Marsella A, Nakane Y and Sartorius N (1992) Cancer incidence of schizophrenic patients. Results of record linkage studies in three countries. British Journal of Psychiatry 161 (Suppl. 18), 75–85.

Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, Bierut LJ and Pato MT and Genomic Psychiatry Cohort Consortium (2014) Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71, 248–254.

Harvey PD and Strassing M (2012) Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry 11, 73–79.

Higgins JPT, Thompson SG, Deeks JJ and Altman DG (2003) Measuring inconsistency in meta-analyses. British Medical Journal 327, 557–560.

Hippisley-Cox J, Vinogradova Y, Coupland C and Parker C (2007) Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Archives of General Psychiatry 64, 1368–1376.

Hodgson R, Wildquist HJ and Busche CJ (2010) Cancer and schizophrenia: is there a paradox? Journal of Psychopharmacology 24 (Suppl. 4), 51–60.

Hung YN, Yang SY, Huang MC, Lung FW, Lin SK, Chen KY, Kuo CK and Chen YY (2014) Cancer incidence in people with affective disorder: nationwide cohort study in Taiwan, 1997–2010. British Journal of Psychiatry 205, 183–188.

Hunt GE, Large MM, Cleary M, Lai HMX and Saunders JB (2018) Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. Drug and Alcohol Dependence 191:234–258.

Hwong A, Wang K, Bents S and Manganur C (2020) Breast cancer screening in women with schizophrenia: a systematic review and meta-analysis. Psychiatric Services 71, 263–268. doi: 10.1176/appi.ps.201900318.

Irwin KE, Steffens EB, Yoon Y, Flores DJ, Knight HP, Pirl WF, Freudenreich O, Henderson DC and Park ER (2019) Lung cancer screening eligibility, risk perceptions, and clinical delivery of tobacco cessation among patients with schizophrenia. Psychiatric Services 70, 927–934.

Islam F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM and Jemal A (2018) Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA: A Cancer Journal for Clinicians 68, 31–54.

Jakobsen AS, Speyer H, Norgaard HCB, Karlsen M, Hjortlof C, Krogh J, Mors O, Nordenfelt M and Toft U (2018) Dietary patterns and physical activity in people with schizophrenia and increased waist circumference. Schizophrenia Research 199, 109.

Ji J, Sundquist K, Sundquist J and Hemminki K (2012) Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry. International Journal of Cancer 131, 2085–2093.

Khan N, Afaq F and Mukhtar H (2010) Lifestyle as risk factor for cancer: evidence from human studies. Cancer Letters 293, 133–143.

Kirkpatrick B and Kennedy BK (2018) Accelerated aging and schizophrenia and related disorders: future research. Schizophrenia Research 196, 4–8.

Kirkpatrick B, Messias E, Harvey PD, Fernandez-Egea E and Bowrie CR (2008) Is schizophrenia a syndrome of accelerated aging? Schizophrenia Bulletin 34, 1024–1032.

Kisely S, Sadek J, MacKenzie A, Lawrence D and Campbell LA (2008) Excess cancer mortality in psychiatric patients. Canadian Journal of Psychiatry 53, 753–761.

Kisely S, Crowe E and Lawrence D (2013) Cancer-related mortality in people with mental illness. JAMA Psychiatry 70, 209–217.

Kisely S, Forsyth S and Laurence D (2016) Why do psychiatric patients have higher cancer mortality rates when cancer incidences the same or lower? Australian and New Zealand Journal of Psychiatry 50, 254–263.
Lawrence D, Holman CD, Jablensky AV, Threlfall TJ and Fuller SA (2000) Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. *Acta Psychiatrica Scandinavica* 101, 382–388.

Li H, Li J, Yu X, Zheng H, Sun X, Lu Y, Zhang Y, Li C and Bi X (2018) The incidence rate of cancer in patients with schizophrenia: a meta-analysis of cohort studies. *Schizophrenia Research* 195, 519–528.

Lichtermann D, Ekelund J, Pukkala E, Tanskanen A and Lönnqvist J (2001) Incidence of cancer among persons with schizophrenia and their relatives. *Archives of General Psychiatry* 58, 573–578.

Lin CY, Lane HY, Chen TT, Wu YH, Wu CY and Wu VY (2013b) Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997–2009. *Schizophrenia Bulletin* 39, 407–416.

Liu NH, Daumit GL, Dua T, Aquila R, Carlsson F, Cuijpers P, Druss B, Dudek K, Freeman M, Fuji J, Gaebel W, Hegerl U, Levav I, Munk Laursen T, Ma H, Ma M, Elena Medina-Mora M, Nordenfelt M, Prabhakaran D, Pratt K, Prince M, Rangaswamy T, Shiers D, Suss F, Thornicroft G, Wahlbeck K, Fekadu Wasse M, Whiteford H and Saxena S (2017) Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. *World Psychiatry* 16, 30–40.

Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaëlsson K, Neovius MA, Erlinge D, Alfredsson L and Ösby U (2015) Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia. *International Journal of Epidemiology* 44, 366–372.

Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusi-Polli P, Dragioti E, Shin JI, Carvalho AF, Stubbs B, Koyanagi A, Kisely S and Correll CU (2020) Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4,717,839 people. *Lancet Psychiatry* 7, 52–63.

Tanskanen A, Tiihonen J and Taipale H (2018) Mortality in schizophrenia: 30-year nationwide follow-up study. *Acta Psychiatrica Scandinavica* 138, 492–499.

Toender A, Munk-Olsen T, Vestergaard M, Larsen JT, Suppli NP, Dalton SO, Vedsted P, Nordentoft M, Mortensen PB and Laursen TM (2018) Impact of severe mental illness on cancer stage at diagnosis and subsequent mortality: a population-based register study. *Schizophrenia Research* 201, 62–69.

Truety C, Buntinx F, De Lepeleire J, De Hert M, Van Winkel R, Aertgeerts B, Bartholomeeuws S and Lesaffre E (2011) Incidence somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data. *BMC Family Practice* 12, 132.

Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, Probst M, Ward PB, Gaughan F, De Hert M, Carvalho AF and Stubbs B (2017) Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. *World Psychiatry* 16, 308.

von Hausswolff-Juhlin Y, Bjartveit M, Lindström E and Jones P (2009) Schizophrenia and physical health problems. *Acta Psychiatrica Scandinavica* Supplement 438, 15–21.

Weiderpass E (2010) Lifestyle and cancer risk. *Journal of Preventive Medicine and Public Health* 43, 459–471.

Westman J, Eriksson SV, Gissler M, Hallgren J, Prieto ML, Bobo WV, Frye MA, Erlinge D, Alfredsson L and Ösby U (2018) Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. *Epidemiology and Psychiatric Sciences* 27, 519–527.

Whitley E, Batty GD, Mulheran PA, Gale CR, Osborn DP, Tynelius P and Rasmussen F (2012) Psychiatric disorder as a risk factor for cancer: different analytic strategies produce different findings. *Epidemiology* 23, 543–550.

World Health Organization (WHO) (2018) WHO fact sheets: schizophrenia. Available at https://www.who.int/news-room/fact-sheets/detail/schizophrenia (Accessed 16 January 2020).

Wu C, Wang YC, Lin CL and Kao CH (2017) Female schizophrenia patients and risk of breast cancer: a population-based cohort study. *Schizophrenia Research* 188, 165–171.

Xipeng Z, Shuai Z, Feijiang Y, Bo C, Shifeng Y and Qihui C (2018) Meta-analysis of the correlation between schizophrenia and breast cancer. *Clinical Breast Cancer* 19, e172–e185.

Xu D, Chen G, Kong L, Zhang W, Hu K, Chen C, Li J and Zhuo C (2017) Lower risk of liver cancer in patients with schizophrenia: a systematic review and meta-analysis of cohort studies. *Oncotarget* 8, 102328–102335.

Zhuo C and Tripplett PT (2018) Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. *JAMA Psychiatry* 75, 363–369.

Zhuo C, Tao R, Jiang R, Lin X and Shao M (2017) Cancer mortality in patients with schizophrenia: systematic review and meta-analysis. *British Journal of Psychiatry* 211, 7–13.

Zhuo C, Zhuang H, Gao X and Tripplett PT (2019) Lung cancer incidence in patients with schizophrenia: a meta-analysis. *British Journal of Psychiatry* 215, 704–711.